FUISZ Announces Filing of Patent Application Relating to New Manufacturing Methods and Compositions for Oral Soluble Films, Superior to Wet Casting Methodologies (Amended Press Release)

Print
| Source: Fuisz Pharma LLC

Bethlehem, PA, April 17, 2017 (GLOBE NEWSWIRE) -- Fuisz today announced the filing of a patent application with the United States Patent & Trademark Office relating to new methods of manufacture for, and new compositions of oral soluble films.

Fuisz principals Richard Fuisz and Joseph Fuisz are long active in oral drug delivery systems.  Richard Fuisz was the primary inventor of the Fuisz Technologies’ shearform matrix quick dissolve tablet (e.g. US 4,855,326).  Richard and Joseph became inventors on the largest wet cast thin film drug delivery patent estate, which has been successfully employed to protect Suboxone® thin film from generic entrants (e.g. US 7,824,588).  They also developed and patented a novel method of achieving sustained drug release in extruded sheets (US 8,613,285), which was acquired by a global consumer products company.  They patented new ways of delivering botanical actives by hot melt extrusion (US 9,125,434).  And they developed a method of making monolayer films with bilayer functionality (US 8,617,589) acquired by a leading oral thin film company.

Joseph Fuisz, Managing Member for Fuisz Pharma LLC commented: “When we first started developing thin film technology (https://en.wikipedia.org/wiki/Thin-film_drug_delivery), we were keen to develop a platform that would address the stability, taste masking and manufacturing cost issues that were challenges for the field of orally disintegrating tablets (https://en.wikipedia.org/wiki/Orally_disintegrating_tablet).  In doing so, our aim was to present a bona fide alternative to conventional tablets, and to overcome the relegation of orally disintegrating tablets to line extension use.   By many metrics, thin film has eclipsed the field of orally disintegrating tablets.  Nonetheless, the limitations of thin film technology have prevented it from becoming a bona fide alternative to conventional tablets as we originally envisioned.”

Joseph Fuisz continued: “With the benefit of extensive reflection on the limitations of current methodologies, we propose new methods and compositions for the field of oral soluble film.”

Richard Fuisz M.D., stated, “Cast film had a long, strong run. Now, we have developed superior new methods and compositions of film that are easier to manufacture, less costly, more accurate dosing, simplified packaging, forms which control abusive drugs, etc. I believe the technology presented in this patent application to be a hallmark achievement in the field of pharmaceutical oral dosage forms.”

Fuisz Pharma LLC is a private pharmaceutical technology company originated by the Joseph Fuisz (https://en.wikipedia.org/wiki/Joseph_Fuisz) and Richard Fuisz (https://en.wikipedia.org/wiki/Richard_Fuisz). The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma. Fuisz Pharma is also active in diagnostic systems. http://www.fuisz.com/.

Joseph Fuisz
jfuisz@fuisz.com
2026695097